Based on several reports showing proof-of-concept results for EV-associated pancreatic cancer biomarkers, GPC1 was the first candidate to enter clinical trials, aiming to evaluate its performance as a biomarker [210]. This evidence concerns the gene GPC1 and familial pancreatic carcinoma.